Skip to main content

Catalyst Calendar

Scope

Tue, Aug 11, 2026

1 updates
IMUX
6:30 AM

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

– Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as NDA and Commercial Readiness – – Pivotal Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis on Track, with Top-Line Data Expected by...

Presentation / Abstract • Phase 2oral presentation Tue, Jun 30, 2026imux.com

Mon, Aug 10, 2026

1 updates
IMUX
4:05 PM

Immunic Appoints Elena Ridloff to Board of Directors

– Appointment Strengthens Board with Financial, Capital Markets and Commercial Leadership Expertise as the Company Approaches Pivotal Phase 3 ENSURE Readout in Relapsing Multiple Sclerosis as well as Potential Regulatory Filings and Commercialization – NEW YORK, August 10, 2026 – Immunic , Inc. (Nasdaq:...

imux.com

Thu, Jul 9, 2026

1 updates
IMUX
6:30 AM

Immunic to Participate in Investor Conferences in July

NEW YORK, July 9, 2026 – Immunic , Inc. (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor conferences in July: July 14-15: Leerink Partners Therapeutics Forum....

imux.com

Wed, Jun 10, 2026

1 updates
IMUX
6:30 AM

Immunic to Participate in Investor, Industry and Scientific Conferences in June

NEW YORK, June 10, 2026 – Immunic, Inc. (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor, industry and scientific conferences in June: June 15-16: H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit....

imux.com